Company Overview and News
Popular marijuana stocks fell across the board Wednesday, paring extreme gains so far this year, as investors cashed in a bit of their bet as Canada became the largest country to legalize the recreational use of cannabis.
STZ.B ACB WEED ACBFF CRON DTK STZ CGC
3h investorplace - 2
When it comes to cannabis, we’ve come a long way since former President Bill Clinton denied ever inhaling. With the previous presidential administration’s frankness on the matter, marijuana has become more blasé. Naturally, marijuana stocks have also increased in popularity, where we have more choices today than was previously thought possible.
IGCIW MNTR IGC ACBFF DTK HEMP CANN LXX CVSI CBIS SRNA LDSYF MJNA APH AMMJ ACAN ABBV SMG LXRP INQD MDCL MSC.H CARA RMHB POTN ACB IIPR IMLFF KAYS PKPH TRTC GRNH ABBV APHQF
[Editor’s note: Oct. 17, 2018 marks the first day of legal marijuana sales in Canada. As the global finance community watches closely and investors decide which pot stocks to buy, we’ve rounded up all of our marijuana stocks content in one place here.]
ACB ALEAF EAPH CRON WEED ACBFF CGC TLRY SMG
TORONTO/ST JOHN’S, Newfoundland (Reuters) - Canada became the first industrialized nation to legalize recreational cannabis on Wednesday, but a lawful buzz will be hard to come by in its biggest cities like Toronto and Vancouver, where stores are not yet open.
ACB WEED ACBFF CGC
Shares of companies in the cannabis business were broadly, and in many cases sharply lower, despite marijuana becoming fully legal in Canada. The ETFMG Alternative Harvest ETF MJ, -3.04% tumbled 6.5% in morning trade, with 27 of 37 components trading lower, to extend Tuesday's 3.7% pullback. Among the more active pot stocks, Canopy Growth Corp. CGC, -4.02% dropped 8.2%, Tilray Inc. TLRY, -6.37% lost 6.
IGCIW ABRW ACB IGC WEED ACBFF CRON NBEV CGC TLRY
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
ACB APH WEED ACBFF APHQF CGC
begin 644 ACB8A101718.pdf M)5!$1BTQ+C,*)79E
2018-10-16 investorplace - 1
The timing looks pretty good for Aurora Cannabis (OTCMKTS:ACBFF), which is a top Canadian cannabis operator. This week, Canada will legalize marijuana for recreational purposes. Then later in the month, Aurora Cannabis stock will be listed on the New York Stock Exchange.
ACB WEED ACBFF DTK CGC TLRY
2018-10-16 investorplace - 5
I’ll agree that if an investor is going to invest in pot stocks, Canopy Growth (NYSE:CGC) is the way to go. While the valuation of CGC stock still looks high, that’s true across the sector, and there is a big opportunity here. Meanwhile, the $4 billion investment into Canopy Growth stock by Constellation Brands (NYSE:STZ) gives the company more than enough capital as well as valuable experience and expertise in the consumer space.
STZ.B ACB PG CRON WEED ACBFF KO STZ CGC TLRY
Altria Group Inc. (MO - Free Report) , America’s leading cigarette manufacturer, is in talks with Canadian cannabis producer Aphria Inc to buy a stake in it, The Globe & Mail reported last week.
STZ.B ACB PEP APH WEED ACBFF CTRL STZ APHQF CGC MO
VANCOUVER, British Columbia, Oct. 15, 2018 (GLOBE NEWSWIRE) -- ICC Labs Inc. (ICC or the Company) (TSX-V: ICC) confirms that the management information circular dated October 3, 2018 (the Circular), form of proxy and other materials with respect to the Company’s proposed plan of arrangement (the Arrangement) with Aurora Cannabis Inc. (Aurora) have been mailed to holders (the ICC Shareholders) of common shares of ICC (the ICC Shares) of record as of September 26, 2018 in accordance with an interim order of the Supreme Court of British Columbia.
2017-12-09 - Asif
Aurora Cannabis is a community minded, Canadian owned and operated company. Nestled in the shadow of the Rockies in Mountain View County, its plants are carefully brought to harvest in its purpose-built 55,200 square foot facility. Fed with water from the Canadian Rockies, cared for in a state-of-the-art facility designed to produce the cleanest, safest medical cannabis available on the market, we're proud of its facility, its team and its product. Cultivating, harvesting, and selling Canadian Medical Marijuana, Aurora is your best chance to experience the healing power of nature. On November 27th, 2015 Aurora was officially issued its license to sell. This marked a monumental step in the continued success and evolution of Aurora as one of Canada's top medical marijuana companies. Aurora is one of 35 licensed producers across Canada and the only one located in Alberta. Boasting the second highest square footage approved for production in Canada, Aurora was the first applicant ...
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
as of ET